SAB BIOTHERAPEUTICS, INC. Increase (Decrease) in Accounts Payable
SAB BIOTHERAPEUTICS, INC. (SABS) reported Increase (Decrease) in Accounts Payable of $789.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $674.88K, a 389.65% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was $114.12K, a 83.32% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was $324.53K, a 45.03% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $336.27K, a 149.79% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2025 was $1.48M, a 60.59% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2024 was $923.32K.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2023 was -$2.70M.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in accounts payable for fiscal 2022 was -$779.42K.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 6 month as first filed | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $674.88K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $789.00K 10-Q · filed 2026-08-06 | $1.11M derived: sum of 3 quarters · filed 2026-08-06 | $1.45M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $114.12K 10-Q · filed 2026-05-12 | $438.65K derived: sum of 2 quarters · filed 2026-05-12 | $774.91K derived: sum of 3 quarters · filed 2026-05-12 | $912.74K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $324.53K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $660.79K derived: sum of 2 quarters · filed 2026-03-09 | $798.62K derived: sum of 3 quarters · filed 2026-08-06 | $1.48M 10-K · filed 2026-03-09 | |
| 2025-09-30 | $336.27K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $474.10K derived: sum of 2 quarters · filed 2026-08-06 | $1.16M 10-Q · filed 2025-11-14 | $1.75M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $137.83K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $822.00K 10-Q · filed 2026-08-06 | $822.34K 10-Q · filed 2025-08-07 | $1.41M derived: sum of 3 quarters · filed 2026-08-06 | $1.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $684.17K 10-Q · filed 2026-05-12 | $1.27M derived: sum of 2 quarters · filed 2026-05-12 | $1.41M derived: sum of 3 quarters · filed 2026-05-12 | $1.36M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $590.38K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $725.00K derived: sum of 2 quarters · filed 2026-03-09 | $679.97K derived: sum of 3 quarters · filed 2026-03-09 | $923.32K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $134.62K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $89.58K derived: sum of 2 quarters · filed 2025-11-14 | $332.94K 10-Q · filed 2025-11-14 | $227.16K derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$45.04K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $198.32K 10-Q · filed 2025-08-07 | $92.55K derived: sum of 3 quarters · filed 2025-08-07 | -$228.13K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $243.36K 10-Q · filed 2025-05-09 | $137.58K derived: sum of 2 quarters · filed 2025-05-09 | -$183.09K derived: sum of 3 quarters · filed 2025-05-09 | -$224.21K derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | -$105.77K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$426.45K derived: sum of 2 quarters · filed 2025-03-31 | -$467.56K derived: sum of 3 quarters · filed 2025-03-31 | -$2.70M 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$320.68K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$361.79K derived: sum of 2 quarters · filed 2024-11-06 | -$2.60M 10-Q · filed 2024-11-06 | -$4.40M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | -$41.11K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$2.28M 10-Q · filed 2024-08-08 | -$4.08M derived: sum of 3 quarters · filed 2024-08-08 | -$3.54M derived: sum of 4 quarters · filed 2024-08-08 | |
| 2023-03-31 | -$2.23M 10-Q · filed 2024-05-20 | -$4.04M derived: sum of 2 quarters · filed 2024-05-20 | -$3.50M derived: sum of 3 quarters · filed 2024-05-20 | -$3.54M derived: sum of 4 quarters · filed 2024-05-20 | |
| 2022-12-31 | -$1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-29 | -$1.26M derived: sum of 2 quarters · filed 2024-03-29 | -$1.30M derived: sum of 3 quarters · filed 2024-03-29 | -$779.42K 10-K · filed 2024-03-29 | |
| 2022-09-30 | $540.69K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | $502.94K derived: sum of 2 quarters · filed 2023-11-13 | $1.03M 10-Q · filed 2023-11-13 | $1.36M derived: sum of 4 quarters · filed 2023-11-13 | |
| 2022-06-30 | -$37.76K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-21 | $485.06K 10-Q · filed 2023-08-21 | $823.38K derived: sum of 3 quarters · filed 2023-08-21 | -$573.20K derived: sum of 4 quarters · filed 2023-08-21 | |
| 2022-03-31 | $522.82K 10-Q · filed 2023-05-15 | $861.14K derived: sum of 2 quarters · filed 2023-05-15 | -$535.45K derived: sum of 3 quarters · filed 2023-05-15 | $1.42M derived: sum of 4 quarters · filed 2023-05-15 | |
| 2021-12-31 | $338.33K derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-04-28 | -$1.06M derived: sum of 2 quarters · filed 2023-04-28 | $900.84K derived: sum of 3 quarters · filed 2023-04-28 | -$2.94M 10-K/A · filed 2023-04-28 | |
| 2021-09-30 | -$1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $562.51K derived: sum of 2 quarters · filed 2022-11-14 | -$3.27M 10-Q · filed 2022-11-14 | ||
| 2021-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$1.88M 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | -$3.84M 10-Q · filed 2022-05-12 | ||||
| 2020-12-31 | $5.21M 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |